Results 71 to 80 of about 4,164 (194)

The Role of Wnt Signaling in Age‐Related Alveolar Bone Loss and Regeneration

Journal of Periodontal Research, EarlyView.
The graphical abstract summarizes key signaling pathways involved in bone formation and resorption associated with Wnt signaling across young and aged long bone and jaw tissues. Levels of evidence are indicated as robust, moderate, or emerging, reflecting the current experimental support in each context.
Hsiao H. Sung, Navya Chalamalasetty, Ali Alzainal, Hanlong Liu, Lexuan Wang, Pietra Colacrai Arikita, Ivy C. X. Wei, Hom‐Lay Wang, M. H. J. van den Bosch, Michelle S. Caird, Peter M. van der Kraan, Kenneth M. Kozloff, Esmeralda Blaney Davidson   +12 more
wiley   +1 more source

Effect of Romosozumab Treatment in Postmenopausal Women With Osteoporosis and Knee Osteoarthritis: Results From a Substudy of a Phase 3 Clinical Trial

ACR Open Rheumatology
Objective Romosozumab is a bone‐forming agent approved for osteoporosis treatment. Here we report results of the protocol‐specified, noninferiority osteoarthritis substudy of the fracture study in postmenopausal women with osteoporosis (FRAME), which ...
Nancy E. Lane, Donald Betah, Cynthia Deignan, Mary Oates, Zhenxun Wang, Jen Timoshanko, Aliya A. Khan, Neil Binkley   +7 more
doaj   +1 more source

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park, Shihyun Kim, Seo‐Yeong An, Reuben H. Kim, Jongho Choi, Moon‐Young Kim   +5 more
wiley   +1 more source

Molecular pathophysiology of chronic kidney disease–mineral and bone disorder: Focus on the fibroblast growth factor 23–Klotho axis and bone turnover dynamics

Experimental Physiology, EarlyView.
Abstract Chronic kidney disease–mineral and bone disorder (CKD‐MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease.
Alief Waitupu, Laras Pratiwi, Henry Sutanto, Djoko Santoso, Decsa Medika Hertanto   +4 more
wiley   +1 more source

Sclerostin antibodies as novel anabolic therapy for osteoporosis

Остеопороз и остеопатии, 2019
Osteoporosis medications are dividedinto two groups: those inhibiting bone resorption and formation (bisphosphonates and denosumab), and those stimulating bone formation i.e. having an anabolic effect. The latter include teriparatide, parathyroid hormone
Elizaveta O. Mamedova, Tatiana A. Grebennikova, Zhanna E. Belaya, Liudmila Y. Rozhinskaya   +3 more
doaj   +1 more source

Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Mucopolysaccharidosis Type IV is a multisystem lysosomal storage disease characterized by severe skeletal dysplasia resulting from impaired degradation of the glycosaminoglycans keratan sulfate and chondroitin‐6‐sulfate. The condition is classified into Types A and B based on the underlying enzyme deficiency.
Mark Wijnen, Evert F. S. van Velsen, J. Gert‐Jan Milhous, Esmee Oussoren, Bram C. J. van der Eerden, Margreet A. E. M. Wagenmakers   +5 more
wiley   +1 more source

Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Osteoporosis is a prevalent skeletal disorder characterised by progressive reduction in bone mass, microarchitectural deterioration, and increased fracture susceptibility. In India, approximately one‐third of the elderly population is affected by bone‐related disorders, and the global burden of osteoporosis continues to rise.
Pramoda G., Kamini Shivhare, Piyush Kumar Gupta, Amirhossein Sahebkar, Prashant Kesharwani, Rahul Shukla   +5 more
wiley   +1 more source

The effects of romosozumab combined with active vitamin D3 on fracture healing in ovariectomized rats

Journal of Orthopaedic Surgery and Research, 2022
Background In this study, we investigated the potential acceleration of fracture healing and bone mineral density-increasing effects of romosozumab and active vitamin D3 combination therapy for fractures in ovariectomized rats.
Ryota Takase, Yuta Tsubouchi, Takefumi Otsu, Takashi Kataoka, Tatsuya Iwasaki, Masashi Kataoka, Hiroshi Tsumura   +6 more
doaj   +1 more source

Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics [PDF]

, 2020
Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase III randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin ...
bovijn, jonas, Boxall, Ruth, Censin, Jenny C., chen, Chia-Yen, Chen, Zhengming, Davey Smith, George, Ferreira, Teresa, Glastonbury, Craig A., Holmes, Michael V, krebs, kristi, Laber , Samantha, Li, Liming, Lin, Kuang, Lindgren, Cecilia M, Milani, Lili, Millwood, Iona Y, Mägi, Reedik, Neale, Benjamin M, pulit, sarah, Walters, Robin G.   +19 more
core   +2 more sources

Secondary Publication: Use of Romosozumab Against Osteoporosis

Tokyo Women's Medical University Journal
In recent years, osteoporosis has become a significant issue in developed countries. Romosozumab, which was introduced in 2019, is a relatively novel drug used for osteoporosis treatment.
Ayako Tominaga, Keiji Wada, Ken Okazaki
doaj   +1 more source